All In Biotech

Drug Trial Radar · NCT03329911

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

A Multicenter, Randomized, Double Blind, Phase III Study of BAT1706 Versus EU Avastin® Plus Chemotherapy in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 651 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

651

Actual

Start

Oct 20, 2017

Primary completion

Nov 5, 2019

Study completion May 27, 2021

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously untreated advanced non-squamous non-small cell lung cancer (nsNSCLC) to demonstrate clinical equivalence of BAT1706 and EU Avastin®.

Conditions

  • Non-squamous Non-small Cell Lung Cancer

Interventions

  • EU Avastin®Drug

    100 mg/4 mL

  • BAT1706Drug

    100 mg/4 mL

  • PaclitaxelDrug

    200 mg/m²

  • carboplatinDrug

    target area under the curve \[AUC\] 6 mg/mL•minute

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: Week 18

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Clinical Medical Research S.C.

    Orizaba, Mexico

  • National Hospital Oncology

    Bloemfontein, South Africa

  • Baskent University Ankara Hospital

    Ankara, Turkey (Türkiye)

  • CI Kryvyi Rih Oncological Dispensary of DRC

    Kryvyi Rih, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.